HCV Treatment
Investigational HCV Inhibitor TMC435 Demonstrates Promising Safety and Efficacy in Phase 1 Study
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 02 April 2010 14:02
- Written by Liz Highleyman
Tibotec's investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 demonstrated good antiviral activity and appeared to be safe and generally well-tolerated in a Phase 1 placebo-controlled clinical trial, according to a report in the March 2010 Gastroenterology.
Older Hepatitis C Patients Have More Side Effects from Interferon-based Therapy, but Many Can Achieve Sustained Response
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 March 2010 14:02
- Written by Liz Highleyman
Chronic hepatitis C patients age 65 or older may experience more adverse events and have a higher rate of treatment discontinuation than late middle-aged people when using pegylated interferon plus ribavirin, according to a study from Taiwan published in the March 1, 2010 Journal of Infectious Diseases. Nevertheless, half of older patients with HCV genotype 1 and nearly 80% of those with genotypes 2 or 3 achieved sustained virological response.
Can Some Genotype 1 Chronic Hepatitis C Patients Benefit from Shorter Interferon-based Treatment?
- Details
- Category: HCV Treatment
- Published on Tuesday, 16 February 2010 13:02
- Written by Liz Highleyman
Carefully selected genotype 1 chronic hepatitis C patients who experience rapid virological response (RVR) by week 4 of treatment with pegylated interferon plus ribavirin may be able to achieve sustained virological response (SVR) with 24 instead of 48 weeks of therapy, according to a meta-analysis reported in the January 2010 Journal of Hepatology. However, the researchers cautioned, overall sustained response rates are significantly lower with shorter treatment, and this strategy should only be considered for individuals with low pre-treatment HCV viral load and an undetectable level at week 4.
CROI 2010: IL28B Gene Variation Linked to Spontaneous Clearance and Treatment Response in HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Friday, 12 March 2010 12:48
- Written by Liz Highleyman
A human genetic variation previously shown to predict hepatitis C prognosis in people with HCV alone may play a similar role in HIV/HCV coinfected individuals, according to a set of studies presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco. The IL28B non-risk genotype associated with both spontaneous HCV clearance and response to interferon-based hepatitis C treatment was less common among people of African descent, perhaps helping explain disparities in treatment outcomes.
AASLD 2009: Boosted Narlaprevir plus Pegylated Interferon and Ribavirin Leads to Rapid Viral Suppression in Genotype 1 Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 10 November 2009 12:46
- Written by HIVandHepatitis.com
In the NEXT-1 study, presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) last week in Boston, the experimental HCV NS3 protease inhibitor narlaprevir (formerly SCH 900518), boosted with ritonavir, demonstrated potent antiviral activity in combination with pegylated interferon and ribavirin among treatment-naive patients with genotype 1 chronic hepatitis C. Across the doses tested, 53% to 87% of narlaprevir recipients achieved undetectable HCV RNA by week 4. Nalraprevir/ritonavir demonstrated no unique or treatment-limiting adverse effects.
More Articles...
- Cochrane Review of Pegylated Interferon plus Ribavirin for Hepatitis C Treatment in People with HIV
- Blood Cholesterol May Increase after Successful Hepatitis C Treatment
- Pharmasset Selects Investigational HCV Polymerase Inhibitor PSI-879 for Preclinical Development
- Statins May Increase Antiviral Activity of Hepatitis C Therapies and Delay Development of Resistance
Web Design and Development by